Summary

The global oral biologics market is expected to grow at a significant rate of around 22% during the forecast period. Genetic engineering is used to produce biological medicines, which are made of proteins derived from human genes and these drugs are also derived from a variety of natural sources. These sources include blood and blood components, gene therapy, somatic cells, tissues, and recombinant therapeutic proteins. For therapeutic interventions in conditions including metabolic disease, aging, and inflammatory disorders, biologics is currently one of the most promising approaches. For chronic diseases, oral delivery of such medications has long been recognized as an important goal.

Oral product efficacy for Crohn's and rheumatoid arthritis attracts more moderate patients to the biologics drug and new treatments which will contribute to the growth of the market. For instance, according to the National Institutes of Health (NIH), out of every 100,000 people, 71 are diagnosed with rheumatoid arthritis every year and around 1.5 million Americans have rheumatoid arthritis. Other factors such as the growing prevalence of chronic diseases, increasing government initiatives, technological advancements in research & development by major key players, and increased availability of advanced diagnostics are expected to uplift the oral biologics market growth. For instance, according to the world health organization (WHO), chronic disease prevalence is expected to rise by 57% by 2020.

Novo Nordisk A/S; Biocon; Oramed; Rani Therapeutics; EnteraBio Ltd.; AbbVie Inc.; Enteris BioPharma Inc.; Chiasma, Inc.; Allena Pharmaceuticals; Lilly are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report
“Amongst drug class, glucagon-like peptide 1 (GLP-1) receptor agonist category to witness robust CAGR during the forecast period”
Based on drug class, the market is segmented into glucagon-like peptide 1 (GLP-1) receptor agonist, recombinant enzyme, somatostatin analogue, guanylate cyclase-c agonist, hormone, and others. The glucagon-like peptide 1 (GLP-1) receptor agonist category holds the major market share during the forecast period owing to the rising product approvals, product launches, partnerships, collaborations, mergers & acquisitions by key players, and r&d activities are expected to drive the market growth over the forecast period. For instance, in December 2020, Entera Bio Ltd. announced that the U.S. Food Drug and Administration had revived the company’s Investigational New Drug (IND) application for EB613, orally delivered human parathyroid hormone (1-34) or PTH, for the treatment of osteoporosis patients.

“Amongst disease indication, the diabetes category held a significant share in the market in 2020”
On the basis of disease indication, the market is categorized into diabetes, hyperoxaluria, acromegaly, irritable bowel syndrome (IBS), chronic idiopathic constipation (CIC), and others. Among these, the diabetes category held a significant share of the market in 2020. This is mainly due to the increasing prevalence of type 1 diabetes globally and the rising prevalence of obesity will drive the segmental growth during the forecast period. For instance, as per the International Diabetes Federation (IDF), around 1.2 million youngsters and youths have type 1 diabetes in 2021.

“North America to hold a significant share in the market”
For a better understanding of the market adoption of the oral biologics industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to grow at a substantial CAGR during the forecast period. The major factors such as well-established healthcare infrastructure, and rising incidences of chronic diseases such as cancer, autoimmune diseases, diabetes, arthritis, Alzheimer’s disease, and chronic kidney disease will contribute to the growth of the market. For instance, according to GLOBOCAN 2020, the number of new cancer cases diagnosed was 2,281,658 in the U.S. in 2020. Furthermore, rising investment in research and development activities by the key industry players and an increasing pipeline of products & new product launches in the market are also driving the market growth.

Reasons to buy this report:
• The study includes market sizing and forecasting analysis validated by authenticated key industry experts.
• The report presents a quick review of overall industry performance at one glance.
• The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.
• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.
• The study comprehensively covers the market across different segments.
• Deep dive regional level analysis of the industry.

Customization Options:
The global oral biologics market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

ページTOPに戻る

Table of Contents